%PDF-1.4
%
41 0 obj
<>
endobj
38 0 obj
<>
endobj
159 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-12-03T13:17:18Z
2024-03-29T08:11:53-07:00
QuarkXPressª: AdobePS 8.6 (219)
2024-03-29T08:11:53-07:00
application/pdf
Heather
2001-483march02
uuid:483d83d3-1dd2-11b2-0a00-3508271d5700
uuid:483d83d7-1dd2-11b2-0a00-bf0000000000
endstream
endobj
27 0 obj
<>
endobj
28 0 obj
<>
endobj
42 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
4 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
17 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
20 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
181 0 obj
[186 0 R]
endobj
182 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
/CS0 CS 0 0 0 1 SCN
/GS1 gs
54 54 m
558 54 l
S
BT
/CS0 cs 0 0 0 1 scn
/TT0 1 Tf
0.02499 Tw 8 0 0 8 424.3613 35.9844 Tm
(The Journal of Rheumatology 2002; 29:3)Tj
0 Tw -46.2952 -0.0313 Td
(526)Tj
ET
0 0 0 0 scn
/GS0 gs
101.27 57.26 407.5 -10.84 re
f*
0.5 w
101.27 57.26 407.5 -10.84 re
S
BT
0 0 0 1 scn
/GS1 gs
/TT1 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 74.4 714.5293 Tm
[(Mielants H, )18 (V)111 (eys EM. Ef)18 (fects of tumor necrosis factor )]TJ
/T1_0 1 Tf
0 Tc 0 Tw 22.2631 0 Td
(\002)Tj
/TT1 1 Tf
0.9059 0 Td
(blockade)Tj
0.02499 Tw -23.169 -1.25 Td
(with infliximab in patients with spondyloarthropathy: an open pilot)Tj
0 -1.25 TD
[(study [abstract]. )55 (Arthritis Rheum 2000;43 Suppl:S101.)]TJ
-2.175 -1.25 Td
[(13.)-875 (Claudepierre P)111 (, R)40 (ymer JC, Chevalier X. IL-10 plasma levels)]TJ
2.175 -1.25 Td
[(correlate with disease activity in spondyloarthropathy)65 (. J Rheumatol)]TJ
0 Tw T*
(1997;24:1659-61.)Tj
0.02499 Tw -2.175 -1.25 Td
[(14.)-875 (Dominguez-Lopez ML, Cancino-Diaz ME, Jimenez-Zamudio L,)]TJ
-0.00011 Tc 2.175 -1.25 Td
[(Granados-Arreola J, Bur)18 (gos-V)111 (ar)18 (gas R, Garcia-Latorre E. Cellular)]TJ
0 Tc T*
(immune response to Klebsiella pneumoniae antigens in patients)Tj
T*
(with HLA-B27+ ankylosing spondylitis. J Rheumatol)Tj
0 Tw T*
(2000;27:1453-60.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(15.)-875 (Garrett S, Jenkinson )18 (T)74 (, Kennedy LG, )18 (Whitelock H, Gaisford P)111 (,)]TJ
0 Tc 2.175 -1.25 Td
[(Calin )55 (A. )55 (A)-220 (new approach to defining disease status in ankylosing)]TJ
-0.00011 Tc T*
[(spondylitis: )18 (The Bath )55 (Ankylosing Spondylitis Disease )55 (Activity)]TJ
0 Tc T*
(Index. J Rheumatol 1994;21:2286-91.)Tj
-2.175 -1.25 Td
[(16.)-875 (Calin )55 (A, Garrett S, )18 (Whitelock H, et al. )55 (A)-220 (new approach to defining)]TJ
2.175 -1.25 Td
(functional ability in ankylosing spondylitis: the development of the)Tj
T*
[(Bath )55 (Ankylosing Spondylitis Functional Index. J Rheumatol)]TJ
0 Tw T*
(1994;21:2281-5.)Tj
0.0249 Tw -2.175 -1.25 Td
[(17.)-875 (Bennet PH, Burch )18 (T)80 (A. New )37 (Y)100 (ork Symposium on population studies)]TJ
2.175 -1.25 Td
(in the rheumatic diseases: new diagnostic criteria. Bull Rheum Dis)Tj
0 Tw T*
(1967;17:453-8.)Tj
0.02499 Tw -2.175 -1.25 Td
[(18.)-875 (Mossmann )18 (T)74 (. Rapid colorimetric assay for cellular growth and)]TJ
2.175 -1.25 Td
(survival: application to proliferation and cytotoxicity assays. J)Tj
T*
(Immunol Methods 1983;65:55-63.)Tj
30.825 30 Td
[(19.)-875 (Hansen MB, Nielsen SE, Ber)18 (g K. Re-examination and further)]TJ
2.175 -1.25 Td
(development of a precise and rapid dye method for measuring cell)Tj
T*
[(growth/cell kill. J Immunol Methods 1989;1)37 (19:203-10.)]TJ
-2.175 -1.25 Td
[(20.)-875 (Y)55 (ing Z, Neure I, Grolms M, et al. )18 (Th1/Th2 cytokine patterns in the)]TJ
2.175 -1.25 Td
(joint of rheumatoid arthritis and reactive arthritis patients: analysis)Tj
T*
[(at the single cell level [abstract]. )55 (Arthritis Rheum 1997;40)]TJ
-0.00011 Tc 0 Tw T*
(Suppl:37S.)Tj
0 Tc 0.0249 Tw -2.175 -1.25 Td
[(21.)-875 (Schlaak J, Hermann E, Ringhof)18 (fer M, et al. Predominance of )]TJ
2.175 -1.25 Td
[(Th1-type )18 (T)-257 (cells in synovial fluid of patients with )37 (Y)100 (ersinia-induced)]TJ
T*
(reactive arthritis. Eur J Immunol 1992;22:2771-6.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(22.)-875 (Smeets )18 (TJM, Dolhain REJM, Breedveld FC, )18 (T)70 (ak PP)111 (. )55 (Analysis of)]TJ
0 Tc 2.175 -1.25 Td
(the cellular infiltrates and expression of cytokines in synovial tissue)Tj
T*
(from patients with rheumatoid arthritis and reactive arthritis. )Tj
T*
(J Pathol 1998;186:75-81.)Tj
-2.175 -1.25 Td
[(23.)-875 (Brandt J, Haibel H, Cornely D, et al. Successful treatment of active)]TJ
2.175 -1.25 Td
(ankylosing spondylitis with anti-tumor necrosis factor )Tj
/T1_0 1 Tf
0 Tw 22.0331 0 Td
(\002)Tj
/TT1 1 Tf
0.02499 Tw -22.0331 -1.25 Td
[(monoclonal antibody infliximab. )55 (Arthritis Rheum 2000;43:1346-52.)]TJ
-2.175 -1.25 Td
[(24.)-875 (Firestein GS, Manning )55 (AM. Signal transduction and transcription)]TJ
2.175 -1.25 Td
[(factors in rheumatic disease. )55 (Arthritis Rheum 1999;42:609-21.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(25.)-875 (Barnes PJ, Karin M. Nuclear factor)20 (-\(kappa\)B \227 a pivotal)]TJ
2.175 -1.25 Td
(transcription factor in chronic inflammatory diseases. New Eng J)Tj
0 Tc T*
(Med 1997;336:1066-71.)Tj
ET
Q
Q
q
1 0 0 1 0 -2 cm
0 0 612 792 re
W n
1 0 0 1 0 2 cm
BT
0 g
ET
/GS2 gs
BT
/T1_1 8 Tf
120.092 49 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2002. All rights reserved.)Tj
ET
Q
BT
0 g
/GS3 gs
/T1_2 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS3 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS3 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
56 0 obj
<>
endobj
85 0 obj
<>
endobj
165 0 obj
<>
endobj
46 0 obj
<>
endobj
52 0 obj
<>
endobj
51 0 obj
<>
endobj
77 0 obj
<>stream
HtVpTJ !!K0AH
#@K,52oPab\!: DJK+824*`Խ
gz|{] ~4|Ш:*jXU7 Z\6̏_R
k~3@O;9!%H%XWc]j-'-[dt8A
Vc'#%G]fuq9sav؉"OsɢD2Q.BNkz[cvqLD'骸AZ:K&IC>YBC
*dDn&&[dlӠhZdjyS}'J~ASʑLr9:;r麀[
vo=@IN"}JrH=H=2$c'=-5AI<Կ_߄>{s9&4!ƤIYJ7B43MMyGy<}]gTثڨüBOZAuFaf7W\K-6ݷhʌPMs1[qRTZh*M+ ;*j<(2uA3'F_abZAA5=iX/ҞUUXoҚ.s]O:z~>#/q/BdLf>`&UtS!X=!c2 xQZB13#Dp=&NDh`똲8wٍq\XA%Fޤ?|?K}ỹN{?
OTD!QLdFA#f4條9f F+sZ*PPkT{M!~^ŹW
^fվ,0N̳:(1yPvggҮrWucޙLYx)+"j1AdD
c:V&2;ǴX#U]5UN*qy_nG!Ĝ
$ʏΫ{t>"W'Xq"CFlE
T}]Vv?Zs;72#Iי:;E܇11{dL-j8[jF\1:\8cu8aTу9O0vڣ3VuF.l;g`A}uþ._=GDHS145R5jNԌΟ=C߮,Y_-\@'1W9j5;fLN7W3w\&sCŞ2+-u1؟ ']_Oe[R(&2Z(P#^+_N:/zZiEǓԦ'툥ԩ6xj#l-eS˶twXkbN|E}ҏ/Uu}{8q?/8q$cb,@AmGiՄY2j;` H6mlm'&THS&/;%?=w{߹žL25!䫼1ؘ
ļ40f^s χ$o*a~WdK%̶Sp`IImq8ay;3/Ǚg=ά)df2
,q^ۯ=E9p{ ھql8}g+le^$cùx*aNTJzJzJz3JKueڐ C:G |.ֹd;i(JzN&8 pY&c7bh석KԎi$]`.?D'KgX7K7\+;ʠ+O,^śOv8{
<\MW؋RSߊѻPU n2(CIIϳ}˓3FA>Hke=52.B4G<ao0[+vϰUS+=|El9Ov-KXR?jjKbR&@h
4M+h
6e'oԐIB&Jt#D)n L0xrw
A}mct1-gCe+R+Sͤue"U-Rn,zJx/bR=re~"eEߋT
PA"\J)z%E~ *
Hf}SfxDaIf1,ҽhT2{Pd+&)^MsdLa۫LI#L~$]R)u
n`|l
>9?f7vtנXv8cH
56[zձf:QLuvFSQ[mpxPۜ4%Who
⡞bߋm
{gpWtAp+&Ɗz)8e7mjjWaoS
X|!QM$ReM$I(&,t}{ck~yѺ扺źfD
MFA~]]ޝ<,x1|OQxy<ԄyVUk5jQkժrFSߨ3դjrfC^p8*TIGRè,r-ͫU0k'@7dNb<GGtc#242 T7`P Br\=5Q'>Ȝ"쯬 kvpp:\UȏU.56̛vOCċ\˜Z]U2~5q#-ZK cɧ{/u[?So68Lֹʑ3ѳSN`CMwGؿn[Bߛx.Kf
N8I.?7G1PHVe25Cl.-cMű=
MgRufr }';Ƕx.غl5[(O `+|6M , 6&m9(H*tz1j-ySF'\t!
܁^&5yfX8O7Yc?VVoᵘ=}EFp!eLT/ćIOsR2<>Dα!Cuf$I>/k;j;/=/S !s3<>AFȁC& $HCʅxP`Ec1^oĶO"O W`A,NNJqjɠl(k =rUQEkW X@h`'J89Y>)G|^#-+#Ȗ7T*1OtaQ3WMS+{BˤpHE|QE8A^A Hr 0AB9HB5".Cvn"xIz|`~0Yݰ&GȴiPg}]yEUkr8V$c^Clނ,Am,^2q4l"ڕ_lrŅ.]Ř\w*a#YjLA3.aZ5۠r6B*rM<9;=z]MOl=xtSw^nn_md1`ߣ7Fwz]M\g=:WJ>VaId,$kb
dʡ ƸcvBZr2b@Ia
tBBi2O&Ţ[z;][
اUv*hO)PG]/_μ콼;thj2;X3J0SeF풎5A jwQP%|a;]%Ĵq@j3~8t~D~ҏ[lV[Kϡ_/+PN9v1uRK2$^Lmܵܵ3EgwXv&!ӰAOH%-uMfaUxt|HBP7qsm\}^A5DW9#'b3+k2"L0eAo4:#x*h5Q8MJ9x(TeX3+ճgٍ܂){qux--X.xξl[|1Af[*%Vj{.Gq~?̍&r\#k
.E\.>$<#u'LIB"\UxDw$6MA0ؿҨ
+D} TW.q!V# RʤtjxHcz8: ͑s?l\5I";JfxʏwU9{){mxw-M{0%Wnkk^>tᷗ-XD\F:sxO!ڠ1k1Eƭ6&d=
BF_Oz~ ʘ"ѺcY5dng>\2tʚKHW<ʀ!8[*V֤XjVց37N2&Нm }zv=*ESC=8ń]gw%K=pbp .WBCnO$n6::(}P